ESTRO 2025 - Abstract Book

S1522

Clinical – Mixed sites & palliation

ESTRO 2025

All 14 patients participating in the interviews reported ePROMs were easy to complete, took an acceptable amount of time, and made them feel better supported.

Conclusion: This study showed that using ePROMs in post-radiotherapy follow-up care is feasible and acceptable to patients based on completion rates and feedback. ePROMs effectively captured severe early side effects during the typically unsupported period between radiotherapy completion and the first follow-up. This highlights that ePROMs can be used to guide and personalise patients care.

Keywords: Personalised Follow-up, Radiotherapy, ePROMs

2522

Proffered Paper SHARP - Stereotactic heart ablative radiotherapy: First data of the prospective multicenter SHARP-study (DRKS00027108) Aurelie Gaasch 1 , Sebastian Marschner 1,2,3 , Philipp Hoegen-Saßmannshausen 4 , Elisabetta Sandrini 4 , Nicolaus Andratschke 5 , Panagiotis Balermpas 5 , Luca Boldrini 6 , Angela Romano 6 , Jan Hofmaier 1 , Michael Reiner 1 , Maximilian Niyazi 7,8 , Claus Belka 1,2,9 , Stefanie Corradini 1 1 Radiation Oncology, LMU University Hospital, Munich, Germany. 2 DKTK, German Cancer Consortium Partner site Munich, Munich, Germany. 3 DKFZ, German Cancer Research Center, Heidelberg, Germany. 4 Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany. 5 Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 6 Radiation Oncology, Fondazione Policlinico Universitario “A. Gemelli”, Rome, Italy. 7 Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. 8 DKTK, German Cancer Consortium, Tübingen, Germany. 9 BZKF, Bavarian Cancer Research Center, Munich, Germany